June 13th 2025
Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.
Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers
Breast Cancer Death Rates Drop, but Racial Disparities Linger
Why You Should Attend Patient-Centered Oncology Care in Baltimore